H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO)

H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO)

Summary

On April 15, 2026, H.C. Wainwright lowered its price target on Allogene Therapeutics, Inc.

Description

On April 15, 2026, H.C. Wainwright lowered its price target on Allogene Therapeutics, Inc.

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source

Related coverage